Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results
Globe Newswire•04/11/2026•16:01 ET
0
Key Highlights
- ➤$1.2B cash and investments as of September 30, 2026, funds operations into 2030
- ➤CAPTIVATE interim analysis showed 75% response among first 40 CIDP participants
- ➤MoMeNtum Phase 2 MMN top-line results remain on track for December ’26
- ➤R&D expenses rose to $45.6M from $32.5M year over year
- ➤Q3 net loss was $46.6M, or $0.81 per share
Expert Statements
Marino Garcia, Chief Executive Officer of Dianthus Therapeutics
“The Dianthus team continues to execute on our strategy to build a best-in-disease neuromuscular franchise with claseprubart across gMG, CIDP, and MMN, while advancing an exciting pipeline of potentially best-in-disease bifunctional fusion proteins with DNTH212 and DNTH312.”
Marino Garcia, Chief Executive Officer of Dianthus Therapeutics
“Following top-line results from our Phase 2 MoMeNtum trial of claseprubart in December, we plan to quickly initiate a Phase 3 trial in MMN in 2027.”
Marino Garcia, Chief Executive Officer of Dianthus Therapeutics
“MMN represents a significant market opportunity, characterized by high unmet needs and limited competition.”
Marino Garcia, Chief Executive Officer of Dianthus Therapeutics
“IVIg is the only approved treatment for patients with MMN, and the lack of patient and physician satisfaction with IVIg presents a meaningful opportunity for claseprubart, given its unique potential for a differentiated, best-in-disease profile due to potent inhibition of the classical pathway and preservation of the lectin and alternative pathways while targeting a patient-friendly, 300mg/2mL, self-administered subcutaneous autoinjector once every two weeks.”
Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN)
Phase 3 EMERGE registrational trial of claseprubart in gMG evaluating 300mg/2mL Q2W and 300mg/2mL Q4W on track, with top-line results expected in 2H’28
Get started
Create a free account to read the full story.